Portage Biotech Inc. develops clinical-stage immuno-oncology therapies for cancer, with news centered on its multi-targeted pipeline and related financing, listing and governance developments. Company updates describe biologic and small-molecule programs including PORT-6, a selective A2A antagonist, and PORT-7, a selective adenosine A2B receptor inhibitor, with disclosures covering combination approaches, preclinical mesothelioma data and the ADPORT-601 clinical program.
Recurring Portage news also includes fiscal-year financial results, research and development expense trends, Nasdaq continued-listing compliance and ordinary-share transactions, including stock-for-stock investment activity involving Compedica Holdings Limited.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.